Page 30 - Peter Marks News Today

The FDA has approved Casgevy and Lyfgenia, the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

The FDA has approved two new gene therapies for sickle cell disease, a 'functional cure' for many patients

LOS ANGELES, Dec. 8 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years and older.

The FDA approved two new therapies for sickle-cell disease, including the worlds first-ever approved CRISPR therapy.

The Centers for Disease Control and Prevention says 100,000 Americans are living with sickle cell disease.

The Centers for Disease Control and Prevention says 100,000 Americans are living with sickle cell disease.

The Centers for Disease Control and Prevention says 100,000 Americans are living with sickle cell disease.

The FDA has approved two new gene therapies for sickle cell disease, a 'functional cure' for many patients

The Food and Drug Administration Friday approved a new sickle cell disease treatment using the CRISPR genome editing technology. It's the first approved human gene editing therapy.

The Centers for Disease Control and Prevention says 100,000 Americans are living with sickle cell disease.